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Abstract
Invariant natural killer T cells (iNKTs) are innate-like T cells that are highly concentrated in the liver and recognize lipids
presented on the MHC-like molecule CD1d. Although capable of a myriad of responses, few essential functions have been
described for iNKTs. Among the many cell types of the immune system implicated in metabolic control and disease, iNKTs
seem ideally poised for such a role, yet little has been done to elucidate such a possible function. We hypothesized that lipid
presentation by CD1d could report on metabolic status and engage iNKTs to regulate cellular lipid content through their
various effector mechanisms. To test this hypothesis, we examined CD1d deficient mice in a variety of metabolically stressed
paradigms including high fat feeding, choline-deficient feeding, fasting, and acute inflammation. CD1d deficiency led to a
mild exacerbation of steatosis during high fat or choline-deficient feeding, accompanied by impaired hepatic glucose
tolerance. Surprisingly, however, this phenotype was not observed in Ja18
2/2 mice, which are deficient in iNKTs but express
CD1d. Thus, CD1d appears to modulate some metabolic functions through an iNKT-independent mechanism.
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Introduction
In recent years, it has become increasingly clear that molecules
and cells classically associated with the immune system have
important roles in maintenance of whole body energy metabolism.
Several mouse strains deficient in cytokines or chemokines are
either protected from or prone to obesity and insulin resistance [1].
In addition, nearly every cell type classically associated with the
immune system—macrophages [2,3], conventional T cells [4,5,6],
eosinophils [7], mast cells [8], B cells [9]—has been implicated in
the control or pathogenesis of obesity-associated morbidity. It has
been suggested that inflammation may inhibit peripheral usage of
glucose in order to spare energy for lymphocytes, whose activation
depends directly on glucose availability [10]. However, any switch
away from the normal homeostatic set point must be reversible; if
energy redistribution is indeed a purposeful role of some
components of the immune system, other components should
turn back the switch when the immune response has resolved. An
overarching rationale for how and why the various cells of the
immune system orchestrate metabolic processes remains elusive.
Invariant natural killer T cells (iNKTs) are innate-like
lymphocytes that co-express NK markers such as NK1.1 with a
semi-invariant ab T cell receptor and show an activated/memory
phenotype even in naı ¨ve animals. Unlike conventional T cells,
iNKTs are selected on and activated by the lipid-presenting MHC
class 1b molecule CD1d, which is constitutively expressed on
hepatocytes and other parenchymal cells, as well as antigen-
presenting cells [11]. Also unlike conventional T cells, activation of
iNKTs can occur through presentation of not only exogenous,
pathogen-derived lipids but also endogenous lipids in combination
with pro-inflammatory cytokines [12]. While present in typical
lymphatic organs such as the spleen and bone marrow, iNKTs are
surprisingly abundant in the liver, where they constitute up to 50%
of liver lymphocytes [13]. Using the model lipid antigen a-
Galactosylceramide to study iNKT biology, numerous effector
functions have been described for these cells, including elaboration
of a vast array of cytokines and chemokines, cytolytic activity, and
activation of NK cells, conventional T cells, macrophages, B cells,
and even regulatory T cells (Tregs) [11]. Yet the physiologic role of
these cells remains ambiguous, largely because very few pathogen-
derived CD1d ligands have been identified. Of note, while the
major CD1d-restricted cell type is invariant NKTs, CD1d can also
present lipids to other unconventional (NK)T cells, which are
lesser in number and remain poorly understood [12].
The curious ability to sense lipids, along with the striking
enrichment of iNKTs amongst hepatic lymphocytes led us and
others to hypothesize that iNKTs might be involved in metabolic
control. Several investigators have reported a pro-atherogenic role
for iNKTs [14,15,16,17,18], and others have observed that the
proportion of hepatic iNKTs is selectively reduced in obese
animals [19,20,21]. Consistent with a pathological role of iNKTs
in obesity and insulin resistance, administration of the NKT
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insulin resistance in obese mice [22]. However, another study
reported that adoptive transfer of NKTs improved steatohepatitis
and glucose intolerance [23], supporting a beneficial role for these
cells. For these reasons and because iNKTs can engage a wide
array of effector mechanisms, we felt they were well poised to
participate in metabolic regulation, but that such a role had been
understudied.
Like iNKTs, CD1d itself has several characteristics that suggest
a role in metabolism. According to public databases, its expression
is highest in liver, white adipose and brown adipose tissue—all
important metabolic organs—rather than on professional antigen-
presenting cells. And although constitutively expressed on many
cell types, CD1d expression is further inducible by PPARc [24], a
master regulator of lipid metabolism that is activated by fatty acids
and other lipids. Thus, much like pathogen-associated molecules
promote MHC class II antigen processing and presentation, lipid
ligand availability may increase CD1d expression. Finally, CD1d
shares trafficking and lipid-loading machinery with lipoprotein
metabolism, where ligands are delivered using lipoprotein
machinery and loaded onto CD1d using the VLDL lipidator,
microsomal triglyceride transfer protein (MTP) [12,25]. Thus, we
hypothesized that, like other classical and non-classical MHC
molecules [26], CD1d reports on cellular status and stress. During
states of lipid imbalance or overload, CD1d may alert iNKT cells,
allowing the immune system to modify the lipid content of
hepatocytes and other metabolically important cells.
To test this hypothesis, we presented CD1d deficient (CD1d
2/2)
mice—which lack CD1d-restricted T cells due to failure of positive
thymic selection [27]—with various metabolic stresses including
high fat feeding, choline-deficient diet, starvation, and endotoxin
injection. In the former but not the later two models, we found
that CD1d
2/2 mice had a subtle but consistent increase in hepatic
triglyceride (TG) accumulation relative to wild type, possibly due
to an increased hepatic lipid uptake from circulation. This was
coupled with a slight worsening of glucose intolerance that was
likely attributable to defective hepatic insulin response. In every
other respect studied, however, CD1d
2/2 mice were indistinguish-
able from wild type controls using available methodology.
Interestingly, in the same high fat feeding model, we observed
no difference between Ja18
2/2 and wild type mice, suggesting
that the slight worsening of metabolic function in CD1d
2/2 mice is
due to non-invariant NKTs, or is attributable for a T cell-
independent function of CD1d.
Materials and Methods
Animal Care and Maintenance
CD1d
2/2 mice (deficient in both CD1d1 and CD1d2)o naB 6
background (backcrossed $10 times), Ja18
2/2 mice on a B6
background (backcrossed $6 times), C57Bl6 mice (NCI or Jackson
Laboratories), and ob/ob mice (6–10 weeks old, Jackson
Laboratories) were maintained on a constant 12-h light:12-h dark
cycle with free access to water and ad libitum access to standard
chow diet (2018s, Harlan Teklad, Madison, WI) unless otherwise
specified. For metabolic phenotyping, male CD1d+/2 mice were
bred to generate knockouts and littermate controls, although
results did not differ from those performed with B6 mice purchase
from NCI or Jackson. Mice were maintained on standard chow
until 6–8 weeks of age before switching to high fat diet (60% kCal
from fat, D12492, Research Diets, New Brunswick, NJ) for 8–16
weeks (depending on the experiment) or choline-deficient diet
(TD.88052, or TD.03118 for controls, Harlan Teklad) for 4 weeks.
Age matched controls were used for all experiments with altered
diets. Chow-fed mice were studied at 7–10 weeks of age. For
fasting experiments, ad libitum chow-fed mice (8–10 weeks old)
were deprived of food with free access to water starting shortly
after the start of the light cycle and blood was collected at the
indicated intervals. For LPS injection, ad libitum fed mice were
injected with 100 ug LPS i.p., and deprived of food for the next
6 hours, after which livers were harvested and flash frozen for
RNA preparation. This study was carried out in accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) of Yale University (Protocol #2008-
08006).
Metabolic parameters
Metabolic rate, food intake and activity were measured using
the Comprehensive Laboratory Animal Monitoring System
(Columbus, OH) over 48 hours, and body composition by in vivo
1H magnetic resonance spectroscopy (MiniSpec, Bruker). For lipid
analyses, plasma harvested from overnight fasted or fasted/refed
(4 hrs) were snap frozen in liquid nitrogen and stored at 280C
until analysis. Triglyceride and NEFA were measured using
enzymatic kits (Triglyceride SL, Genzyme Diagnostics, Canada
and NEFA-HR Wako, Richmond, VA) according to the
manufacturer’s instructions. For tissue lipid analysis, tissues were
collected from overnight fasted mice (unless otherwise noted), snap
frozen, and stored at 280 until analysis. Lipids were extracted by
2:1 chloroform:methanol according to the Folsch method [28]
from equal masses of tissue and then assayed using enzymatic kits
(Triglyceride SL and Cholesterol Assay Kit, Cayman Chemical,
Ann Arbor, MI) or by
31P NMR (Avanti, Alabaster, AL). To
measure hepatic lipid export, 4 hr-fasted mice were injected with
1 g/kg poloxamer 407 (Pluronic F-127, Sigma) and plasma was
collected at the indicated timepoints for analysis by Triglyceride
SL. For microscopy, mice were fasted overnight prior to sacrifice.
Livers were fixed in 4% paraformaldehyde for 8 hours, subjected
to a sucrose gradient to preserve architecture, and embedded in
OCT freezing media. Frozen sections were stained with Oil Red
O as described [29] and visualized by light microscopy (Nikon).
Glucose Tolerance Tests (GTT), Insulin Tolerance Tests
(ITT), and Pyruvate Tolerance Tests (PTT)
For the GTT, overnight fasted mice were injected i.p. with
1.0 g/kg (for CD1d
2/2 and WT) or 0.75 g/kg (for Ja18
2/2 and
WT) glucose. Blood was sampled from the retro-orbital plexus
before injection and at the indicated times and glucose was
measured using a OneTouch Ultra glucometer (LifeScan,
Milpitas, CA). Concurrently collected plasma samples were frozen
at 220C until insulin ELISA (Crystal Chem). For the ITT, 4 hr-
fasted animals were injected i.p. with 1.0 U/kg of human
recombinant insulin (Novolin, Novo Nordisk, Denmark). For the
PTT, overnight fasted mice were injected i.p. with 2.0 g/kg
sodium pyruvate.
Hyperinsulinemic-Euglycemic Clamp
A jugular venous catheter was implanted 6 to 7 d before the
hyperinsulinemic-euglycemic clamps. To assess basal whole-body
glucose turnover, after overnight fast, [3-
3H]-glucose (HPLC
purified; Perkin-Elmer Life Sciences) was infused at a rate of
0.05 mCi/min for 120 min into the jugular catheter. Following the
basal period, hyperinsulinemic-euglycemic clamps were conducted
in conscious mice for 140 min with a 3 min primed (31.5 mU/kg)
followed by a continuous [4.5 mU/(kg-min)] infusion of human
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3H]-
glucose (0.1 mCi/min), and a variable infusion of 20% dextrose to
maintain euglycemia (,120 mg/dL). Plasma samples were
obtained from the tip of the tail at 0, 30, 50, 65, 80, 90, 100,
110, 120, 130 and 140 min. The tail incision was made at least 2 h
before the first blood sample was taken to allow for acclimatiza-
tion, according to standard operating procedures [30]. Also, mice
received an i.v. albumin-containing solution mimicking artificial
plasma during the insulin-stimulated period of the clamp to
compensate for volume loss secondary to blood sampling. At the
end of the clamps, mice were anesthetized with pentobarbital
sodium i.v. injection (150 mg/kg) and all tissues were taken within
4 min, snap-frozen in liquid nitrogen, and stored at 280uC for
subsequent analysis. Plasma glucose (10 mL per sample) was
measured using a YSI 2700D glucose analyzer. For the
determination of
3H-glucose, plasma was deproteinized with
ZnSO4 and Ba(OH)2, dried to remove
3H2O, resuspended in
water, and counted in scintillation fluid (Ultima Gold; Perkin-
Elmer Life Sciences).
Rates of basal and insulin-stimulated whole-body glucose
turnover were determined as the ratio of the [3-
3H]-glucose
infusion rate (disintegrations per minute, dpm) to the specific
activity of plasma glucose (dpm/mg) at the end of the basal period
and during the final 30 min of steady state of the clamp,
respectively. Endogenous glucose production was calculated by
subtracting the glucose infusion rate from the whole-body insulin-
stimulated glucose disposal. Whole body glycolysis rate was
estimated by the ratio of delta
3H2O [dpm/(mL-min)] to the
specific activity of plasma glucose (dpm/mg) at the end of the basal
period and during the final 30 min of the clamp.
Flow Cytometry
iNKTs were analyzed using a variation of published methods
[31]. In brief, spleens were mechanically dissociated using frosted
glass slides and red blood cells were removed with Ack lysis buffer
(Gibco). Livers were mechanically dissociated and mononuclear
cells were isolated by centrifugation on a 67.5%/44% isotonic
Percoll gradient (GE Healthcare). Bilateral epididymal white
adipose tissue (WAT) was dissociated in PBS containing Liberase
TM (Roche) and stromal vascular cells (pellet) were separated from
adipocytes (floating) by centrifugation. Cell surface staining was
performed using commercially available antibodies against B220
(clone RA3-6B2), CD3e (145-2C11), CD4 (GK1.5), CD8a (53-
6.7), CD69 (H1.2F3), CD25 (PC61.5), NK1.1 (PK136) and BrdU
(BD Biosciences and eBioscience), and Annexin V (Invitrogen).
PBS57-loaded CD1d tetramers and empty tetramer were provided
by the NIH tetramer facility (Emory University, Atlanta, Georgia)
and regularly titrated to optimal concentration. For BrdU
incorporation experiments, 6-month high fat fed mice were
injected i.p. daily with 1 mg BrdU for 7 days. Cells were analyzed
using a BrdU flow cytometry kit (BD Biosciences). Cells were
analyzed on FACSCalibur or LSR II (BD Biosciences) using
FACSDiva software (BD Biosciences) and FlowJo (Treestar).
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
For analysis of gene expression, total RNA was isolated from
liver, hypothalamus, or epididymal white adipose tissue by
phenol/chloroform extraction followed by cleanup with RNeasy
(Qiagen) according to the manufacturer’s instructions. Hypothal-
ami were excised from the brain along the borders of the anterior
commisure and third ventricle. Poly(A) mRNA was reverse
transcribed and PCR was performed using intron-spanning gene
specific primers (sequences are available upon request) and SYBR
green master mix (Qiagen or Quanta) on a Stratagene machine
(Agilent Technologies). Fold change in mRNA expression was
determined using the DDcT method normalize to HPRT, RPL13a,
or both. A list of examined genes is included in Table S1.
Protein analysis
CXCL16 expression was measured using a RayBio Cytokine
Array III membrane according to the manufacturer’s instructions.
Spot density was determined using Image J and normalized to
positive control spots.
Statistical Analysis
Data are expressed as means 6 SEM. Statistical significance
was determined by t-test or two-way ANOVA, as appropriate.
Statistically significant results are reported for p,0.05.
Results
iNKTs are selectively decreased in obese livers
Consistent with previous reports [19,20,21,32], we found that
high fat feeding led to a significant reduction of PBS57-CD1d
tetramer+ iNKTs in the liver (Figure 1A&E) but not in the spleen
(Figure 1A). However, when expressed as an absolute number of
cells but not as a percentage, iNKTs were slightly increased in
WAT. This difference between percentage and numbers of iNKTs
in the WAT was attributable to the greater number of WAT
stromal vascular cells isolated from obese animals, such that an
increase in WAT iNKT numbers was dwarfed by much larger
increases in other infiltrating populations; this is consistent with the
dramatic increase of macrophages and other inflammatory cells
observed during obesity [3]. However, when expressed as an
absolute number of cells, iNKTs, conventional T cells and CD4+
T cells were slightly increased, and CD8+ cells were dramatically
increased (Figure 1B).
Depletion of iNKTs from obese livers could be due to at least
one of four potential causes: increased apoptosis, defective
homeostatic maintenance, activation-induced death or receptor
internalization, or migration elsewhere. We observed an increased
percentage of Annexin V positive cells among NK1.1+CD3e+ cells
in obese mouse livers (Figure 1C), consistent with published results
in high fat-fed mice [20]. However, we sought to address the
possibility that other factors were also contributing to a reduced
iNKT population. Recent thymic emigrant iNKTs are largely
NK1.1-, and acquire NK1.1 in the periphery in the CD1d-
dependent manner [33]. We observed no difference in NK1.1
staining, or in BrdU incorporation into hepatic iNKTs (Figure 1D),
suggesting that neither proliferation nor maturation of iNKTs
were altered in the obese state. We did not observe any increase in
staining for activation markers such as CD69 or CD25 in hepatic
iNKTs from obese mice, although, interestingly, we observed a
small shift in these markers in hepatic CD3e+, tetramer- T cells
(Figure 1E). We also did not observe increased PD-1 staining in
hepatic iNKTs from obese mice, although this has been
determined to be a marker of chronically activated and/or
exhausted iNKTs [34,35]. These data suggest that iNKTs are not
activated by chronic high fat diet or in the obese state, although we
cannot rule out the possibility that activation may have occurred at
some earlier time.
CD1d and CXCL16 expression are changed by metabolic
state
If iNKTs regulate metabolism, it would be expected that CD1d
presentation or iNKT cell localization would be altered by
changes in metabolic state. We found that CD1d mRNA
Impact of CD1d Deficiency on Metabolism
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increase in WAT of genetically obese ob/ob mice (Figure 2A).
Interestingly, CD1d expression in the WAT and hypothalamus was
also sensitive to acute changes in feeding and fasting in lean
animals, although expression was not altered in the liver under
these conditions (Figure 2B). CXCL16:CXCR6 interactions are
thought to contribute to iNKT homing to and retention in the
liver [36,37]. We found that CXCL16 mRNA and protein
expression was dramatically reduced in obese mice relative to
lean controls (Figure 2C&D), offering an alternative explanation
for the reduced hepatic iNKT numbers seen in the obese state.
CD1d
2/2 mice are metabolically normal when fed a
standard diet, and gain weight equally on a high fat diet
To address whether alterations in liver CD1d expression and/or
iNKTs reflected a cause or consequence of metabolic changes
during obesity, we examined the physiology of lean, chow-fed
CD1d
2/2 and controls. We found that the body weight of these
animals was indistinguishable (Figure 3A), and that the plasma
glucose response to an insulin tolerance test (Figure 3B) or glucose
tolerance test (Figure 3C) was identical. Furthermore, insulin
secretion in response to a glucose tolerance test did not differ
(Figure 3D). Thus CD1d
2/2 mice appear normal on a standard
diet.
CD1d deficiency worsens DIO-associated glucose
intolerance
To probe the role of CD1d in diet-induced obesity (DIO),
CD1d
2/2 mice were fed a high fat diet (60% kCal from fat for 12
weeks). CD1d
2/2 mice gained the same amount of weight as
controls (Figure 4A) and had indistinguishable fat and muscle
composition (Figure 4B). Caloric intake, metabolic rate, activity,
and whole body substrate utilization were not different between
genotypes (Table 1). However, when challenged with an
intraperitoneal glucose bolus, we found that obese CD1d
2/2 mice
demonstrated slightly worsened glucose intolerance compared to
controls (Figure 4C, left panel). Of note, by performing at least 7
similar experiments, we determined that a minimum of ,12
Figure 1. iNKTs are selectively decreased in obese livers. A) The percentage (left panel) of tetramer+, CD3e-int iNKTs among total CD3e+B220-
lymphocytes is decreased in the liver but not the spleen of mice made obese through 6 months of HFD compared to controls, as is the absolute
number of hepatic iNKTs (right panel) (n=4 mice/group). B) The number of CD8+ T cells in the epididymal white adipose tissue of 4 month HFD-fed
mice is increased relative to controls, while the numbers of tetramer+ iNKTs, total CD3e+, tetramer- non-iNKTs, and CD3e+, tetramer-, CD4+ cells is
non-significantly increased (n=11/group). C) ob/ob mice (blue line) have an increased percentage of AnnexinV+ cells among NK1.1+, CD3e+ hepatic
iNKTs but not conventional T cells, compared with lean controls (red line). Representative of 2 experiments. D) The percentage of (left panel) NK1.1+
hepatic iNKTs (gated on B220-, CD3e-int, tetramer+ cells) does not differ between chow-fed and 4 week HFD-fed mice (n=4/group), nor does BrdU
incorporation into iNKTs (representative of 2/group). E) Hepatic iNKTs from 9-week HFD-fed mice do not show evidence of acute activation
(representative of 3 experiments).
doi:10.1371/journal.pone.0025478.g001
Figure 2. CD1d and CXCL16 expression are changed by metabolic state. A) CD1d mRNA expression is reduced in livers of ob/ob mice,
whereas it is non-significantly increased in the WAT (n$5/group). B) CD1d mRNA expression is induced by feeding in the hypothalamus and WAT, but
not the liver, of lean B6 mice (n$4/group). C) CXCL16 mRNA expression is reduced in the livers of ob/ob mice (n=5–6/group). D) CXCL16 protein level
in mice fed regular chow or high fat diet for 3 months (pooled from 5/group).
doi:10.1371/journal.pone.0025478.g002
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significant difference; this demonstrates that the effect size
observed is quite small. Fasting plasma glucose and insulin
measured at the start of glucose tolerance testing (GTT) did not
differ between genotypes (Figure 4C), although there was a strong
trend for increased fasting plasma insulin concentrations in
CD1d
2/2 mice, consistent with a trend to increased insulin
resistance. Plasma insulin excursion during the GTT did not
significantly differ between groups (p=0.19 by 2 way ANOVA),
although CD1d
2/2 mice demonstrated increased plasma insulin
concentrations at 30 minutes, past the peak of insulin secretion in
control mice (Figure 4C, right panel). These data indicate that
worsened insulin resistance, rather than defective insulin secretion,
is the most likely cause of worsened glucose intolerance in CD1d
2/2
mice. An insulin tolerance test (ITT, Figure 4D) and pyruvate
tolerance test (PTT, Figure 4E) demonstrated a consistently strong
trend toreduced insulinsensitivity inCD1d
2/2 mice,although these
tests did not reach statistical significance. Thus, CD1d plays a subtle
role in regulating normal glucose and insulin metabolism during
DIO.
Glucose intolerance in CD1d
2/2 mice is attributable to
decreased hepatic insulin sensitivity
To explore the mechanism of exacerbated glucose intolerance
in CD1d
2/2 mice, we performed hyperinsulinemic-euglycemic
clamp studies [30]. We observed trends towards reduced insulin-
stimulated whole body glucose metabolism (Figure 5A), reduced
peripheral glucose uptake (Figure 5B) and reduced suppression of
hepatic glucose output (Figure 5C). Body mass is a strong predictor
of insulin insensitivity, (Figure 5D), with animals of increasing
body weight generally showing reduced whole body insulin
sensitivity and poorer suppression of hepatic glucose production;
thus, it is recommended that tests of glucose homeostasis compare
weight-matched mice [30]. Because our cohort of wild-type
animals had a large variance in body weight, which could
introduce substantial variation in measurement and obscure
genotype-dependent differences, we reanalyzed our data using a
weight-matched subset that excluded statistical or body weight
outliers. These data demonstrated a strong trend to reduced whole
body insulin sensitivity (Figure 5E) that was attributable to a
significantly impaired suppression of hepatic glucose output
(Figure 5G), rather than a defect in peripheral glucose uptake
(Figure 5F). This suggested that gluconeogenic output and/or
glycogenolysis may be increased in high fat-fed CD1d
2/2 mice
relative to controls. To explore this mechanism, we performed
quantitative RT-PCR on livers, but did not observe any
differences in mRNA expression of glycolytic (glucokinase, Gck or
pyruvate kinase, PKlr) or gluconeogenic (phosphoenol pyruvate carbox-
ykinase, pepck or glucose-6-phosphatase, G6pc) genes in the fasted state
(Figure 5H). It is possible, however, that gene expression may be
abnormal in the hyperinsulinemic state, since basal endogenous
glucose production can be normal in states of insulin resistance
[38].
CD1d deficiency worsens hepatic steatosis on a high fat
diet
A number of studies have shown that increases in intracellular
lipid metabolites can directly cause insulin resistance in both
Figure 3. CD1d
2/2 mice are metabolically normal when fed a standard chow diet. A) CD1d
2/2 mice and their littermates have similar body
weight on normal chow (n=11–12/group). B) Chow-fed CD1d
2/2 and WT mice have identical insulin tolerance tests (n=9–12/group) and C) glucose
tolerance tests. D) Plasma insulin does not differ during a glucose tolerance test (n=9–12/group).
doi:10.1371/journal.pone.0025478.g003
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that are highly enriched amongst intrahepatic lymphocytes [13],
we hypothesized that the primary metabolic disturbance in mice
lacking CD1d (and therefore iNKTs) would most likely be hepatic
lipid metabolism, with insulin resistance as a secondary conse-
quence. We observed an increase in hepatic triglyceride
accumulation with high fat feeding that was more severe in
CD1d
2/2 mice (Figure 6A&B). Liver triglyceride accumulation
appeared to be specific, as we did not detect any alterations in
plasma triglycerides (Figure 6D), consistent with previously
published work showing that CD1d deficiency did not alter
plasma triglyceride or cholesterol content [14,15,16,17], nor did
we observe any difference in plasma free fatty acids in either the
fed or fasted state (Figure 6E). Interestingly, other lipid classes were
differently dysregulated, as there was a trend toward lower
cholesterol content (Figure 6C). Because CD1d is known to bind
Figure 4. CD1d deficiency worsens DIO-associated glucose intolerance. A) Body weight and B) composition do not differ between high fat-
fed CD1d
2/2 and littermates (n=8/group; representative of 2 experiments). C) Glucose tolerance tests demonstrate a slight but statistically significant
worsening of glucose intolerance (left panel) in high fat-fed CD1d
2/2 mice (n=15–16/group). Plasma insulin (right panel) during a glucose tolerance
test is higher in CD1d
2/2 mice. D) CD1d
2/2 mice show a strong trend towards reduced response during an insulin tolerance test (n=10–11/group). E)
CD1d
2/2 mice show a strong trend towards increased blood glucose during a pyruvate tolerance test (n=5–6/group).
doi:10.1371/journal.pone.0025478.g004
Table 1. High fat-fed CD1d
2/2 mice do not differ from
littermates in food intake, energy expenditure or activity.
WT KO t-test
VO2 (ml/kg/min) 2432.53+/240.79 2412.53+/260.74 0.79
VCO2 (ml/kg/min) 1886.74+/239.25 1874.72+/240.55 0.83
RER 0.78+/20.01 0.78+/20.00 0.81
heat (kcal/kg/hr) 11.60+/20.21 11.48+/20.28 0.72
feeding (g/kg/hr) 2.48+/20.14 2.51+/20.07 0.84
activity (counts/hr) 54.22+/24.79 60.30+/26.97 0.48
Comprehensive Laboratory Animal Monitoring System data demonstrates no
difference in VO2, VCO2, RER, heat, feeding, or activity between obese CD1d
2/2
mice and their littermates (n=8/group).
doi:10.1371/journal.pone.0025478.t001
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2/2 mice is attributable to decreased hepatic insulin sensitivity. A) Glucose infusion rate, B)
peripheral glucose uptake, and C) suppression of hepatic glucose output suggest a trend towards hepatic insulin resistance in high fat-fed CD1d
2/2
mice (n=9–13/group). D) Body weight strongly predicts decreased glucose infusion rate and poor suppression of hepatic glucose output; body
weight matched group is shown within the vertical lines. E) Glucose infusion rate, F) peripheral glucose uptake, and G) suppression of hepatic glucose
output excluding body weight outliers shows a significant defect in hepatic insulin sensitivity in CD1d
2/2 mice (n=9–10/group). H) Gene expression
from livers of WT and CD1d
2/2 mice (n=8/group).
doi:10.1371/journal.pone.0025478.g005
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lipids from obese CD1d
2/2 and WT mice by
31P NMR.
Interestingly, several species appeared to be altered in both
quantity and chemical shift (Figure S1 and Table 2). We noted
that the two spectra could not be perfectly aligned, suggesting that
the chemical composition of some of the major species was
different between knockout and WT livers (Figure S1). When we
manually assigned arbitrary identifiers (a–h) to individual peaks,
we found that not only the species composition, but also the
molarity were altered by genotype (Table 2). Thus liver lipid
content is altered qualitatively and quantitatively in CD1d
2/2 mice
when compared to wild type animals on high fat diet.
Hepatic steatosis occurs whenever the positive and negative
fluxes of triglycerides in the liver are unequal. This could be due
to an increase in de novo lipogenesis in the liver, an increase in
lipid uptake from the plasma, a decrease in triglyceride export, or
a reduction in fat oxidation in the liver. To explore the possibility
of defective hepatic triglyceride export in high fat-fed CD1d
2/2
Figure 6. CD1d deficiency worsens hepatic steatosis on high fat diet. A) Representative oil red O staining shows that CD1d
2/2 mice are not
steatotic on a normal diet, but develop more severe hepatic steatosis on a high fat diet. B) Quantitative analysis shows CD1d
2/2 mice have
significantly more hepatic triglyceride accumulation than WT on a high fat diet (n=12–14/group). C) Hepatic cholesterol content trends lower in
CD1d
2/2 mice (n=8/group). D) Plasma triglyceride does not differ in either the fasted or refed state (n=5–6/group). E) Plasma free fatty acids do not
differ in either the fasted (n=17/group) or fed (n=5/group) state.
doi:10.1371/journal.pone.0025478.g006
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surfactant that inhibits lipoprotein lipase and low-density
lipoprotein receptor-mediated uptake of triglyceride into tissue
such that triglyceride exported from the liver accumulates in
plasma [44]. We found that hepatic export was not diminished in
CD1d
2/2 mice (Figure 7A). To investigate other possible
mechanisms indirectly, we examined gene expression of fatty
acid and triglyceride metabolic genes in the liver. We found that
CD1d
2/2 mice had no difference in expression of fatty acid
synthetic or oxidative genes (Figure 7C), but had slightly higher
expression of some fatty acid transporters (Figure 7B), suggesting
increased lipid uptake as a potential mechanism underlying lipid
accumulation in CD1d
2/2 livers. Consistent with a minor
reduction of cholesterol content in CD1d
2/2 livers, several genes
involved in sterol metabolism and detoxification were slightly
altered in CD1d
2/2 livers (Figure S2).
CD1d deficiency worsens metabolic parameters when
mice are fed a choline deficient diet
To examine the effect on glucose homeostasis and hepatic lipid
metabolism in another model of steatosis, independent of obesity,
we examined CD1d
2/2 and WT mice fed a choline-deficient diet.
As expected, choline-deficient diet feeding trended to decrease the
proportion of hepatic iNKTs (Figure 8A), consistent with
published data [45], although mice of both genotypes had a
normal body weight (Figure 8B). Choline-deficient diet induced a
non-significant increase in liver triglyceride content (Figure 8C)
and a slight decrease in plasma triglyceride in CD1d
2/2 mice
relative to controls (Figure 8D). Choline-deficient diet-fed CD1d
2/2
mice also showed an increased glucose excursion during a glucose
tolerance test (Figure 8E), with decreased fasting plasma glucose
(Figure 8F). No clear differences in gene expression that could
Table 2. Altered phospholipid composition of CD1d
2/2 livers.
Species concentration (mM)
abcdef gh
genotype n/a LPA n/a n/a PA n/a n/a n/a
WT 0.170 3.553 0.176 0.068 0.837 0.248 0.71 0.336
KO 0.176 4.246 0.231 0.116 0.928 0.398 0.169 0.161
fold 1.035 1.195 1.313 0.586 1.109 1.605 0.238 0.479
Phospholipid composition measured by
31P NMR shows that the quantity of
several phospholipid species is altered in livers of obese CD1d
2/2 mice relative
to controls (as demonstrated by fold changes). Most peaks could not be
assigned, as indicated by ‘‘n/a’’ (analyzed from a single pooled sample of 8/
group). LPA=lysophosphatidic acid; PA=phosphatidic acid.
doi:10.1371/journal.pone.0025478.t002
Figure 7. Steatosis in CD1d
2/2 mice is most likely due to increased fatty acid uptake. A) Hepatic triglyceride export (VLDL) is not decreased
in DIO CD1d
2/2 mice (n=10–11/group). B) qRT-PCR analysis of obese mouse livers shows increased expression of fatty acid transporters, but C)
unchanged expression of fatty acid and triglyceride synthetic and oxidative genes (n=8/group).
doi:10.1371/journal.pone.0025478.g007
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25478Figure 8. CD1d deficiency worsens metabolic parameters when mice are fed a choline-deficient diet. A) Hepatic iNKTs (as a % of B220-
hepatic mononuclear cells) are (nonsignificantly) reduced by choline-deficient diet. B) Body weight is normal in both CD1d
2/2 and WT mice fed a
choline-deficient diet. C) Liver triglycerides are slightly increased in CD1d
2/2 on choline-deficient diet, whereas D) plasma triglycerides are slightly
decreased. E) Abnormal glucose tolerance observed in CD1d
2/2 on choline-deficient diet with F) decreased fasting plasma glucose. G) No differences
in gene expression are observed in CD1d
2/2 livers (n=7–10/group for all experiments).
doi:10.1371/journal.pone.0025478.g008
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PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e25478explain the increased steatosis or altered glucose homeostasis
were observed (Figure 8G). Thus, the overall metabolic profile of
choline-induced steatosis resembled that induced by high-fat diet
in CD1d
2/2 mice.
iNKT deficiency does not alter fasting tolerance
Given the extremely modest effect of CD1d deficiency on
glucose tolerance and hepatic steatosis during high fat feeding,
we hypothesized that iNKTs may be more important for other
types of metabolic challenges, such as fasting. During fasting,
adipose tissue lipolysis mobilizes fatty acids and glycerol, which
must be converted to ketones and glucose, respectively for use by
other tissues. When CD1d
2/2 mice or controls were subjected to
a 12-hr fast, they lost equal amounts of weight, maintained
plasma glucose and free fatty acids at equivalent levels, and
demonstrated an equal decrement in plasma triglycerides
(Figure 9A). Plasma analytes were also similar in a separate
experiment that extended the period of fasting to 24 hours (data
not shown). Similarly, Ja18
2/2 mice, which lack iNKTs due to a
disruption in the canonical Ja18-Va14 TCR-alpha chain
rearrangement [46] but are sufficient in CD1d, did not differ
from controls in any of these parameters (Figure 9B). At the end
of the fasting period, liver triglyceride levels between CD1d
2/2
mice and controls did not differ (Figure 9C). Gene expression of
important oxidative genes induced during fasting did not differ
between CD1d
2/2 mice and littermates (Figure 9D). These data
suggest no obvious role for CD1d or iNKT cells in metabolic
adaptation to fasting state.
Major metabolic changes induced by LPS stimulation are
not CD1d-dependent
Inflammation and infection are also important metabolic
challenges for which iNKTs may be required. To test the role
of CD1d in this model, we simulated infection by injecting
CD1d
2/2 mice and controls with LPS and measured changes in
metabolic gene expression. Among candidate metabolic genes
previously shown to be changed in the liver by LPS stimulation
[47], none were CD1d-dependent (Figure 10 A–H). Of interest,
however, Fgf21 trended to increase in both unstimulated
(p=0.17) and LPS-stimulated (p=0.08) CD1d
2/2 livers
(Figure 10F), as in fasted CD1d
2/2 livers (Figure 9D), suggesting
there may be a subtle alteration of oxidation or substrate switch
in CD1d
2/2 livers that could not be adequately revealed by any
of our experiments. In comparison to metabolic genes, two
interferon-responsive genes, IRF1 and GBP1, had lower expres-
sion in CD1d
2/2 mice at baseline (Figure 10I&J), consistent with
production of IFNc by iNKTs in basal conditions [48]. We also
found that CD1d
2/2 mice had almost no detectable IL-4 mRNA
in the liver (Figure S3) Although it is not known whether iNKT-
derived IL-4, like IFNc, is translated in the basal state, this may
suggest that iNKTs are also important contributors to hepatic IL-
4 production under basal conditions. Despite this difference, we
did not observe differences in macrophage number or M2
macrophage gene expression. Thus, while iNKTs may contribute
a significant portion of interferons a/b or c and IL-4 in the liver
in unchallenged conditions, these do not appear to contribute
significantly to metabolic adaptations to acute LPS challenge in
the liver.
The metabolic phenotype of CD1d
2/2 mice is
independent of iNKTs
CD1d
2/2 mice are deficient not only in iNKTs, but also other
CD1d-restricted T cells with variable or semi-invariant T cell
receptors [49], as well as CD1d itself. To verify that the phenotype
we observed was attributable to iNKTs, we also examined
Ja18
2/2 mice. Like CD1d
2/2 mice, Ja18
2/2 mice had identical
body weight to WT mice on high fat diet (Figure 11A) After
verifying by FACS that both strains were, indeed, deficient in
iNKTs, we were surprised to find that high fat fed Ja18
2/2 mice
did not develop increased hepatic steatosis (Figure 11B) Moreover,
Ja18
2/2 mice, unlike CD1d
2/2 mice, did not show any trend
towards glucose intolerance on a glucose tolerance test
(Figure 11C), nor did they exhibit abnormally elevated plasma
insulin during the glucose tolerance test (Figure 11D). These data
suggest that the small differences we observed in hepatic
triglyceride accumulation and insulin resistance in CD1d
2/2 mice
are independent of iNKTs and are instead dependent on CD1d-
restricted non-iNKT cells, or on a T-cell-independent role of
CD1d. Additionally, although both strains have been backcrossed
to C57Bl/6 at least 6 times, we cannot rule out the possibility that
the phenotypic differences seen are attributable to small genetic
differences other than CD1d or Ja18, including linked genes.
Discussion
Previous investigators have noted decreases in hepatic iNKTs
during obesity and have implicated iNKTs in either helpful or patho-
logic roles in metabolic syndrome [14,15,16,17,18,19,20,21,22,23].
However, these studies have not examined hepatic lipid content
or whole body glucose homeostasis in CD1d
2/2 mice or Ja18
2/2
mice. Data utilizing knockout or depletion of multiple cell types
simultaneously are difficult to interpret in light of data
demonstrating a role for other types of T cells in metabolism
[4,5,6]. However, during the preparation of this manuscript, a
study was published in which high fat-fed CD1d
2/2 mice were
reported to have glucose tolerance indistinguishable from wild
type and a non-significant trend to increased hepatic triglyceride
accumulation [32]. These data are consistent with ours, and may
differ only in the exceptionally large numbers of animals required
to resolve the small differences we observed, as discussed further
below. Furthermore, our data suggest that the subtle differences
observed between CD1d
2/2 mice and their littermates are not
attributable to iNKTs, as Ja18
2/2 mice do not recapitulate the
phenotype. Thus, we believe that iNKTs play a minimal if any
role in metabolism in the context of diet-induced obesity, while
CD1d plays a small but potentially important role in obesity.
However, we cannot rule out the possibility that iNKTs and/or
CD1d play an important role in metabolic control in a context
not recapitulated by our experiments.
Like other investigators before us [19,20,21], we observed a
selective decrease in iNKTs in the liver of obese animals that was
not seen in the spleen or white adipose, consistent with previously
published results [4,5,6,32]. We did not detect any defect in
Figure 9. iNKT deficiency does not alter fasting tolerance. A) When fasted for 12 hours, CD1d
2/2 and WT mice lose an equal percentage of
body weight, maintain similar blood glucose and FFAs, and experience a similar decay in plasma TG (n=7–8/group). B) When fasted for 12 hours,
Ja18
2/2 and WT mice lose an equal percentage of body weight, maintain similar blood glucose and FFAs, and experience a similar decay in plasma
TG (n=7–8/group). C) Triglyceride content does not differ between CD1d
2/2 and WT mice after fasting (n=4/group). D) Minimal gene expression
differences observed between fasted CD1d
2/2 and WT mice (n=4/group).
doi:10.1371/journal.pone.0025478.g009
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activation. Other investigators have suggested that increased
apoptosis, perhaps due to lipotoxicity, is the cause of reduced
hepatic iNKTs [20]. However, we continue to consider the
possibility that iNKTs may be depleted from fatty livers because of
activation or exhaustion-induced cell death, rather than non-
specific lipotoxicity. A final possible cause of hepatic iNKT
depletion is decreased CD1d and CXCL16-dependent retention
in the liver, perhaps combined with potential upregulation of these
signals in distant sites.
Although indistinguishable from littermates on a chow diet,
CD1d
2/2 mice develop slightly exacerbated insulin resistance on
a high fat diet. Importantly, a large number of animals were
needed to resolve differences seen on a GTT, indicating that the
effect size conferred by CD1d genotype is quite small when
compared against stochastic inter-animal variation seen during
this test. When a perfectly weight-matched group of mice was
analyzed using hyperinsulinemic-euglycemic clamps, a significant
worsening of hepatic insulin resistance was observed in obese
CD1d
2/2 mice, while no significant change in peripheral glucose
uptake was observed. This suggested that the mild exacerbation
of insulin resistance in CD1d
2/2 mice was due to hepatic insulin
resistance.
Accompanying glucose intolerance in both the high fat-fed and
choline-deficient diet-fed mice was increased hepatic TG content.
Phospholipid composition also appeared to be altered, with both
peak amplitude and chemical shift differing between obese
CD1d
2/2 mice and controls. Such chemical shifts may suggest
altered acyl chain length or level of saturation. More elusive,
however, is the cause of these lipid changes. We observed no
difference in hepatic triglyceride export, gene expression related to
de novo triglyceride synthesis, or gene expression related to fat
oxidation. However, we did observe increased hepatic expression
of several fatty acid transporters, suggesting that increased lipid
flux into the liver could be the proximal mechanism leading to
steatosis in these mice. Preference of these transporters for specific
acyl chain types could underlie the altered hepatic phospholipid
composition. Also interesting is the possibility that CD1d itself may
play some role in transport of lipids, perhaps contributing
qualitatively or quantitatively to the lipid composition changes
we observed.
Because the metabolic changes observed in high fat-fed
CD1d
2/2 mice were very small in magnitude, we hypothesized
that high fat feeding was not the most relevant challenge and that
iNKTs and/or CD1d might be more important for metabolic
adaptation during different types of challenges. Other than
Figure 10. Major metabolic changes induced by LPS stimulation are not CD1d-dependent. A–H) Many genes altered by LPS stimulation
are not affected by CD1d deficiency. I) IRF1 expression is reduced in CD1d
2/2 mice at baseline but not after LPS stimulation. J) GBP1 expression is
reduced in CD1d
2/2 mice (n=4/group for all).
doi:10.1371/journal.pone.0025478.g010
Figure 11. The metabolic phenotype of CD1d
2/2 mice is independent of iNKTs. A) Body weight does not differ between high fat-fed Ja18
2/
2 and WT mice. B) Liver triglyceride is not different in high fat fed Ja18
2/2 and WT mice. C) Glucose tolerance is not different in high fat fed Ja18
2/2
and WT mice. D) Plasma insulin does not differ during a glucose tolerance test (n=9–10/group for all panels).
doi:10.1371/journal.pone.0025478.g011
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metabolic demands are dramatically changed. When we examined
CD1d
2/2 mice or Ja18
2/2 mice during fasting, however, we
observed no difference in any measured metabolic parameter
compared to controls. Similarly, in LPS-challenged mice, gene
expression changes in metabolic pathways were not altered by
CD1d expression. A small trend towards increased Fgf21
expression was noted, however, in fasted mice, ad libitum fed mice,
and ad libitum fed LPS-injected mice. Interestingly, recent data
from Ricardo-Gonzalez et al. suggested that IL-4 signaling
through STAT-6 in the liver could inhibit expression of PPARa
target genes such as Fgf21 [50]. Given the dramatic reduction in
IL-4 expression in CD1d
2/2 livers, this may suggest that iNKTs
contribute some but not all of the IL-4 protein in the liver under
basal conditions, leading to a mild version of the phenotype
observed by Ricardo-Gonzalez et al. This phenotype does not
appear to be connected to either the steatosis or glucose
intolerance observed in our model, as these were iNKT-
independent. While it is well known that iNKTs express many
untranslated cytokine mRNAs in the unstimulated state [51], and
that some translation of IFNc mRNA occurs in normal, healthy
mice [48], it is not yet clear whether IL-4 is also translated. Our
observed changes in Fgf21 expression may suggest that IL-4
translation does occur, but does not appear to contribute
substantially to metabolic control in any of the experimental
paradigms examined in this study.
IL-4 is also thought to be important for polarizing macrophages
towards an ‘‘alternatively activated’’ state. Alternatively activated
macrophages, in turn, have been suggested to improve oxidative
metabolism, counteracting the insulin resistance induced by
‘‘classically activated’’ inflammatory macrophages [52,53,54].
Despite the reduction in IL-4 expression in CD1d
2/2 mice, we
did not observe any difference in macrophage numbers or
polarization. Therefore, iNKT-derived cytokines are unlikely to
be responsible for the observed metabolic changes in CD1d
2/2
mice.
Some data presented herein may suggest that the metabolic
phenotype of CD1d
2/2 mice is completely independent of T cells:
CD1d expression is regulated in the brain, for example, which is
devoid of T cells under normal conditions. Few roles for CD1d
outside of antigen presentation to T cells have been elucidated,
although some investigators have suggested that CD1d could
signal internally to induce NKT-independent cytokine production
[55]. However, because CD1d can bind and shield hydrophobic
acyl chains and traffic between cellular compartments, it is possible
to imagine its involvement in lipid transport outside of antigen
presentation or cytokine production. For example, while micro-
somal triglyceride transfer protein (MTP) assists in CD1d
lipidation, CD1d might contribute amphipathic lipids for MTP-
dependent VLDL assembly. It will be very interesting to see
whether CD1d does indeed play such a role, and whether this
contributes to the altered lipid composition of CD1d
2/2 livers.
In conclusion, we have found that CD1d
2/2 mice have mildly
exacerbated hepatic triglyceride accumulation associated with
hepatic insulin resistance when fed a steatogenic diet. There is
ample circumstantial evidence to suggest that iNKTs would be
appropriate mediators of lipid metabolism in the liver, as well as
evidence that the absence of iNKTs led to reductions in cytokines
shown to be important in metabolism. Surprisingly, however, the
phenotypes we observed in CD1d
2/2 mice did not repeat in
Ja18
2/2 mice, and thus are likely to be independent of iNKTs.
While we were unable to find any role for CD1d or iNKTs in
inflammation or fasting-induced metabolic changes, and only a
minimal role for CD1d in the context of high fat feeding, it
remains possible that CD1d and/or iNKTs play an important role
in metabolic control in a context not recapitulated by our
experiments, or in general, outside of the natural environment.
Supporting Information
Figure S1 Altered phospholipid composition of CD1d
2/2
livers. Phospholipid composition measured by
31P NMR shows
that the quantity and chemical shift of several phospholipid species
is altered in livers of obese CD1d
2/2 mice relative to controls
(analyzed from a single pooled sample of 8 mice/group).
(TIF)
Figure S2 Altered expression of genes involved in sterol
metabolism and detoxification in CD1d
2/2 livers. (n=8
mice/group).
(TIF)
Figure S3 Macrophage-related gene expression in
CD1d
2/2 mice. (n=8 mice/group).
(TIF)
Table S1 Gene list for quantitative PCR analyses.
(TIF)
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